

## **SUCCESSFUL LAUNCH of MyHealthTest**

MyHealthTest (MHT) was successfully launched yesterday, at the Canberra Innovation Centre to coincide with the commencement of National Diabetes Week. Speakers included Mr Rod Kafer (former Australian Rugby player and current Fox Sports commentator) who has been living with diabetes since he was 15 and Ms Gil Cramer the CEO of ACT Diabetes.

MHT's first entry into the testing market will be the test used to diagnose and monitor diabetes (the "HbA1c" test). At the launch it was announced that MHT would provide a free test to all 3,500 members of ACT Diabetes when the test becomes available at the end of July.

A research article published in the BMC Clinical Pathology Journal on 8<sup>th</sup> July 2015 by researchers at the ANU John Curtin School of Medicine showed MHT's Dried Blood Spots gave comparable results to venous collected whole blood samples and were in agreement with the gold-standard for HbA1c testing.

More information about MHT and the research article can be found at :  
[www.myhealthtest.com](http://www.myhealthtest.com)

This follows on from the announcement in April that MHT had been awarded an Accelerating Commercialisation grant of up to \$1 million from the Commonwealth Department of Industry and Science to fast track the roll out of its HbA1c test.

ITL has previously announced it had, subject to shareholder approval, secured the exclusive opportunity to acquire up to 100% of MHT, a Canberra based direct to consumer pathology test provider, through a series of call options to be exercised subject to certain milestones being achieved.

ITL, in conjunction with its legal advisors, have been progressing draft Notice of Meeting documents through the ASX and ASIC. An EGM will then be convened for shareholders to approve the proposed transactions in respect of MHT.

Bill Mobbs  
Executive Chairman

**ITL Limited** ABN 16 088 212 088  
**Unit 1, 63 Wells Road**  
**Chelsea Heights, Victoria, 3196**

ITL is a diversified healthcare company, specialising in innovative medical devices and procedure packs for global healthcare markets. ITL manufactures in Australia and Malaysia, and has sales offices in Australia, North America, and Asia.

ITL's patented medical devices have a presence in over 50 countries and protect healthcare workers in millions of procedures annually. ITL supplies its range of customised medical procedure packs to over 200 hospitals across Australia.

**Australian Securities Exchange**  
Code: ITD

**Ordinary Shares**  
84,678,177  
**Board of Directors**

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director

Trevor Doolan	Company Secretary
David Holden	Chief Financial Officer

**ITL Contact**  
Trevor Doolan      Company Secretary  
Phone:                +61 3 8773 3050  
Email:                [info@itl-limited.com](mailto:info@itl-limited.com)

**[www.itl-limited.com](http://www.itl-limited.com)**

**Media**  
Ben Knowles      Walbrook IR  
Phone:                +61 426 277 760  
Email:                [ben.knowles@walbrookir.com.au](mailto:ben.knowles@walbrookir.com.au)